# Open-label Trial of Leukine in Active Crohn's Disease

> **NCT00206700** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 378 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Sargramostim (Leukine)

## Key facts

- **NCT ID:** NCT00206700
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-02
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 378 (ACTUAL)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206700, "Open-label Trial of Leukine in Active Crohn's Disease". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT00206700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*